NASDAQ:XBIO Xenetic Biosciences Q1 2026 Earnings Report $3.03 0.00 (0.00%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$2.88 -0.15 (-4.79%) As of 05/22/2026 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Xenetic Biosciences EPS ResultsActual EPS-$0.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXenetic Biosciences Revenue ResultsActual Revenue$0.81 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXenetic Biosciences Announcement DetailsQuarterQ1 2026Date5/12/2026TimeAfter Market ClosesConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsXenetic Biosciences' Q2 2026 earnings is estimated for Friday, August 7, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xenetic Biosciences Earnings HeadlinesCritical Survey: Nature's Sunshine Products (NASDAQ:NATR) and Xenetic Biosciences (NASDAQ:XBIO)May 19, 2026 | americanbankingnews.comXenetic Biosciences Grants Equity Award to Interim CEOApril 27, 2026 | theglobeandmail.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.May 26 at 1:00 AM | Weiss Ratings (Ad)Xenetic extends R&D collaboration with The Scripps Research InstituteNovember 19, 2025 | msn.comXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comXenetic 735,000 share Spot Secondary priced at $6.12October 10, 2025 | msn.comSee More Xenetic Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email. Email Address About Xenetic BiosciencesXenetic Biosciences (NASDAQ:XBIO) is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders. At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets. By integrating these platforms, the company aims to create therapeutics with enhanced efficacy, favorable dosing profiles and better patient compliance. Xenetic’s lead programs have progressed through preclinical development and early-stage clinical trials, with an emphasis on oncology immunotherapy and enzyme replacement therapies. The company collaborates with academic institutions and industry partners to advance its candidates and to explore new applications of its delivery and targeting technologies. Research and development activities are centralized in the United States, supported by strategic operations in Europe. Headquartered in Boston, Massachusetts, Xenetic is committed to innovation in biologics and small-molecule therapeutics. Led by a team with deep expertise in protein engineering, drug development and regulatory strategy, the company continues to build a pipeline aimed at improving outcomes for patients with serious and life-threatening conditions. Xenetic Biosciences is publicly traded on the NASDAQ under the ticker XBIO.View Xenetic Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
